Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).

The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug ...

Another week of escalating tariff talks led to a slump across major U.S. stock market indices for the five-day trading period ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Charles Schwab Investment Management Inc. cut its stake in shares of Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report) by 11.6% in the 4th quarter, according to its most recent filing with the ...

soon-to-be-discontinued Alzheimer's drug simufilam. The U.S. Supreme Court upheld on Wednesday a regulation targeting largely untraceable "ghost guns" imposed by Democratic former President Joe ...

soon-to-be-discontinued Alzheimer's drug simufilam. Legalcategory· March 25, 2025 Ripple Labs says it settles with US SEC, will pay reduced $50 million fine Ripple Labs agreed to settle a U.S ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...